BCA
BPMC

Berman Capital Advisors’s Blueprint Medicines BPMC Stock Holding History

Berman Capital Advisors’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$2K Hold
29
– – ﹤0.01% 1661
2021
Q2 		$2K Hold
29
– – ﹤0.01% 1566
2021
Q1 		$2K Sell
29
-4
-12% -$399 ﹤0.01% 1481
2020
Q4 		$3K Hold
33
– – ﹤0.01% 1271
2020
Q3 		$3K Hold
33
– – ﹤0.01% 1173
2020
Q2 		$2K Buy
33
+7
+27% +$473 ﹤0.01% 1243
2020
Q1 		$1K Buy
+26
New +$1.67K ﹤0.01% 1253

Other funds holding BPMC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

Berman Capital Advisors's BPMC Position: Q3 2021 in Review

Berman Capital Advisors held its Blueprint Medicines (BPMC) position steady in Q3 2021 at 29 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #1661.

Berman Capital Advisors first reported a position in BPMC in Q1 2020 and has held it in 7 quarters since. The position peaked at $3K in Q4 2020. 288 funds tracked by Wall St. Rank hold BPMC as of Q3 2021.

  • Berman Capital Advisors held 29 shares of Blueprint Medicines worth $2K as of Q3 2021.
  • Berman Capital Advisors left its Blueprint Medicines share count unchanged in Q3 2021.
  • Blueprint Medicines made up ﹤0.01% of Berman Capital Advisors's portfolio in Q3 2021, its #1661 holding.
  • Berman Capital Advisors first reported a position in Blueprint Medicines in Q1 2020 and has held it in 7 quarters since.
  • Berman Capital Advisors's Blueprint Medicines position peaked at $3K in Q4 2020.
  • 288 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2021.

Based on Berman Capital Advisors's 13F filing for Q3 2021, filed 7 Oct 2021.